Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Conn. Nurse Pleads Guilty to Prescribing Pain Meds for Drug-Company Kickbacks

By Drug Discovery Trends Editor | June 29, 2015

A nurse admitted in federal court to prescribing pain medications in exchange for kickbacks from a drug company, according to authorities.

Heather Alfonso, 42, admitted prescribing the powerful painkiller Subsys, made by the Arizona-based Insys Therapeutics, in exchange for $83,000 in payments over two years, according to the U.S. Attorney’s Office for the District of Connecticut.

The guilty plea, announced June 23, comes amid an ongoing investigation into Insys, federal authorities confirmed.

Alfonso worked as an advanced practice registered nurse at the Comprehensive Pain and Headache Treatment Center in Derby, Conn.

She admitted submitting more than $1 million claims related to Subsys prescriptions – and was the most prolific prescriber of the drug in Connecticut, according to the authorities.

Most of the patients who were prescribed the drug did not have cancer – but were taking the drug to treat chronic pain, according to Medicare Part D beneficiaries who were interviewed afterward.

Federal investigators alleged that Alfonso was paid as a speaker at more than 70 dinner programs, at the cost of about $1,000 per event. But Alfonso did not give any kind of presentation at the majority of the events, they added.

A message left for an attorney for Alfonso was not returned. Insys has not returned a message left at their Arizona headquarters.

Subsys is a fentanyl-based spray which is indicated for chronic pain for cancer patients.

Sentencing is scheduled for Sept. 17. Alfonso faces a maximum of five years in prison and $250,000 in fines.

Insys was the subject of an investigation by The New York Times last year involving healthcare federal payment databases, and the off-label use of Subsys.


Filed Under: Drug Discovery

 

Related Articles Read More >

The FDA’s AI ambitions depend on better data practices
Researchers working in the clinical laboratory
Outpatient clinics are becoming critical Infrastructure for drug trials
SAS launches clinical trial analytics software built on its Viya cloud native analytics platform
Bayer’s Lynkuet approved by FDA for menopausal hot flashes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE